Xenon Pharmaceuticals Inc
NASDAQ:XENE
Xenon Pharmaceuticals Inc
Cash from Financing Activities
Xenon Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Cash from Financing Activities
$353.5m
|
CAGR 3-Years
60%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
Zymeworks Inc
NYSE:ZYME
|
Cash from Financing Activities
$81.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Financing Activities
$842k
|
CAGR 3-Years
-85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cash from Financing Activities
$142m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Financing Activities
-$5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Financing Activities
CA$5.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
See Also
What is Xenon Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
353.5m
USD
Based on the financial report for Dec 31, 2023, Xenon Pharmaceuticals Inc's Cash from Financing Activities amounts to 353.5m USD.
What is Xenon Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
26%
Over the last year, the Cash from Financing Activities growth was 27%. The average annual Cash from Financing Activities growth rates for Xenon Pharmaceuticals Inc have been 60% over the past three years , 26% over the past five years .